India’s Reliance Life Sciences has applied for regulatory approval to begin early stage human trials of its COVID-19 vaccine candidate, The Economic Times reported on Thursday.
The unlisted firm’s parent Reliance Industries did not immediately respond to a Reuters request for comment. Reuters
